This latter pathway is of particular interest in breast cancer as HER2 is often upregulated in both invasive and in situ disease and is associated with poor prognosis tumours (Slamon et al, 1987; Sposto and Silverstein, 2002). The gene discussed is ERBB2; the disease is breast cancer.